Notably, expression of GREB1 is a predictive biomarker for breast cancer endocrine resistance22,23 and low expression of GREB1 is associated with reduced relapse-free survival in 742 patients with ER+ breast cancer treated with endocrine therapy24 (logrank P = 0.0056) (Fig. 1g). Here, GREB1 is linked to breast carcinoma.